Regulus Therapeutics Inc.

NasdaqCM:RGLS Stock Report

Market Cap: US$104.1m

Regulus Therapeutics Future Growth

Future criteria checks 0/6

Regulus Therapeutics is forecast to grow earnings and revenue by 22.6% and 76.1% per annum respectively while EPS is expected to grow by 9.6% per annum.

Key information

22.6%

Earnings growth rate

9.6%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate76.1%
Future return on equityn/a
Analyst coverage

Good

Last updated12 Dec 2024

Recent future growth updates

Recent updates

Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth

Sep 28
Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth

Regulus surges 15% after Phase 1 data for kidney disease candidate

Sep 12

Regulus Therapeutics GAAP loss per share narrows

Aug 11

Does Regulus Therapeutics (NASDAQ:RGLS) Have A Healthy Balance Sheet?

Oct 12
Does Regulus Therapeutics (NASDAQ:RGLS) Have A Healthy Balance Sheet?

The Read On Regulus Therapeutics

Aug 03

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now

Jun 09
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now

Regulus reports top-line data from early-stage RGLS4326 trial in polycystic kidney disease

May 03

Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)

Mar 13
Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)

Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year

Mar 10
Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year

Regulus Therapeutics announces closing of $19.4M private placement

Dec 08

Regulus Therapeutics EPS beats by $0.17, beats on revenue

Nov 05

Earnings and Revenue Growth Forecasts

NasdaqCM:RGLS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026N/A-123N/AN/A3
12/31/2025N/A-85N/AN/A6
12/31/2024N/A-48N/AN/A6
9/30/2024N/A-42-36-36N/A
6/30/2024N/A-35-34-33N/A
3/31/2024N/A-31-28-27N/A
12/31/2023N/A-30-27-27N/A
9/30/2023N/A-29-28-27N/A
6/30/2023N/A-28-27-27N/A
3/31/2023N/A-29-28-27N/A
12/31/2022N/A-28-26-26N/A
9/30/2022N/A-29-27-27N/A
6/30/2022N/A-30-26-26N/A
3/31/2022N/A-29-25-25N/A
12/31/2021N/A-28-24-24N/A
9/30/20215-22-13-13N/A
6/30/202110-15-12-12N/A
3/31/202110-16-12-12N/A
12/31/202010-16-13-13N/A
9/30/20205-19-21-21N/A
6/30/20200-23-21-21N/A
3/31/20200-21-22-21N/A
12/31/20197-19-20-20N/A
9/30/20197-22-19-19N/A
6/30/20197-27-26-26N/A
3/31/20197-36-32-32N/A
12/31/20180-49-43-43N/A
9/30/20180-55-50-50N/A
6/30/20180-60N/A-51N/A
3/31/20180-68N/A-56N/A
12/31/20170-72N/A-59N/A
9/30/20170-77N/A-63N/A
6/30/20170-81N/A-67N/A
3/31/20171-81N/A-67N/A
12/31/20161-82N/A-57N/A
9/30/201612-69N/A-59N/A
6/30/201614-63N/A-55N/A
3/31/201617-62N/A-48N/A
12/31/201521-56N/A-50N/A
9/30/201514-71N/A-44N/A
6/30/201513-67N/A-41N/A
3/31/201510-58N/A-42N/A
12/31/20148-57N/A-40N/A
9/30/20149-36N/A-37N/A
6/30/201414-29N/A-33N/A
3/31/201418-24N/A-30N/A
12/31/201320-19N/A-28N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RGLS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RGLS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RGLS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RGLS is forecast to have no revenue next year.

High Growth Revenue: RGLS is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if RGLS's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 22:20
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Regulus Therapeutics Inc. is covered by 17 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James BirchenoughBMO Capital Markets Equity Research
James BirchenoughBMO Capital Markets U.S. (Historical)
Madhu KumarB. Riley Securities, Inc.